709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
LORUSSO, D; Y XIANG; K HASEGAWA; G SCAMBIA; Leiva GÁLVEZ et al.
709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
Autoři
LORUSSO, D; Y XIANG; K HASEGAWA; G SCAMBIA; Leiva GÁLVEZ; P Ramos ELIAS; A ACEVEDO; Markéta BEDNAŘÍKOVÁ; A.J.P.D.S. GOMES; F Contreras MEJIA; A REISS; F ZAGOURI; J-Y LEE; V SAEVETS; A AYHAN; P LIU; K U YAMADA; M PUGLISI; S PIGNATA a L DUSKA
LORUSSO, D; Y XIANG; K HASEGAWA; G SCAMBIA; Leiva GÁLVEZ; P Ramos ELIAS; A ACEVEDO; Markéta BEDNAŘÍKOVÁ; A.J.P.D.S. GOMES; F Contreras MEJIA; A REISS; F ZAGOURI; J-Y LEE; V SAEVETS; A AYHAN; P LIU; K U YAMADA; M PUGLISI; S PIGNATA a L DUSKA. 709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. In Annals of Oncology. 2024. Dostupné z: https://doi.org/10.1016/j.annonc.2024.08.771.
@proceedings{2440317, author = {Lorusso, D and Xiang, Y and Hasegawa, K and Scambia, G and Gálvez, Leiva and Elias, P Ramos and Acevedo, A and Bednaříková, Markéta and Gomes, A.J.P.D.S. and Mejia, F Contreras and Reiss, A and Zagouri, F and Lee, JandY and Saevets, V and Ayhan, A and Liu, P and Yamada, K U and Puglisi, M and Pignata, S and Duska, L}, booktitle = {Annals of Oncology}, doi = {https://doi.org/10.1016/j.annonc.2024.08.771}, language = {eng}, title = {709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study}, year = {2024} }
TY - CONF ID - 2440317 AU - Lorusso, D - Xiang, Y - Hasegawa, K - Scambia, G - Gálvez, Leiva - Elias, P Ramos - Acevedo, A - Bednaříková, Markéta - Gomes, A.J.P.D.S. - Mejia, F Contreras - Reiss, A - Zagouri, F - Lee, J-Y - Saevets, V - Ayhan, A - Liu, P - Yamada, K U - Puglisi, M - Pignata, S - Duska, L PY - 2024 TI - 709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study ER -
LORUSSO, D; Y XIANG; K HASEGAWA; G SCAMBIA; Leiva GÁLVEZ; P Ramos ELIAS; A ACEVEDO; Markéta BEDNAŘÍKOVÁ; A.J.P.D.S. GOMES; F Contreras MEJIA; A REISS; F ZAGOURI; J-Y LEE; V SAEVETS; A AYHAN; P LIU; K U YAMADA; M PUGLISI; S PIGNATA a L DUSKA. 709O Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: Overall survival results from the randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. In \textit{Annals of Oncology}. 2024. Dostupné z: https://doi.org/10.1016/j.annonc.2024.08.771.